How does this company make money?
The company sells sensors as consumables — each one lasts 10-15 days, so patients must keep buying replacements continuously. Payment flows primarily through insurance rather than directly from patients: Medicare covers the sensors under durable medical equipment and pharmacy benefit codes, and commercial insurers do the same. The 10-15 day use cycle means a steady, repeating revenue stream tied to the number of active users wearing sensors at any given time.
What makes this company hard to replace?
The FDA requires a separate 510(k) clearance submission for every competing CGM device, which takes 12-18 months and must be completed before a competitor's sensor can be prescribed or reimbursed. Insulin pump manufacturers like Tandem and Insulet certify their automated dosing software against specific devices, so switching sensors also means losing that pump integration until the new device goes through its own software certification. Insurance prior authorisation is tied to specific device codes, so a patient switching to a different CGM system must go through a new approval process with their insurer.
What limits this company?
The biocompatible adhesive must hold a waterproof seal against skin for up to 15 days without causing allergic reactions across very different skin types. Formulating to that standard requires specialised biochemistry expertise that cannot be handed off to outside manufacturers. Because that work stays in-house, how fast the company can produce and quality-check the adhesive sets the ceiling on how many sensors can ship.
What does this company depend on?
The company cannot operate without FDA 510(k) clearance for each sensor generation, a reliable supply of glucose oxidase enzyme for the biosensor to function, Bluetooth radio frequency spectrum for transmitting readings, Medicare and commercial insurance reimbursement codes that make the sensor affordable to patients, and lithium battery cells rated to run continuously for 10-15 days.
Who depends on this company?
Type 1 diabetics using automated insulin delivery systems like Tandem t:slim pumps rely on the device's continuous, certified glucose data to drive automated dosing — without it, those pumps cannot dose automatically. Endocrinologists managing insulin-dependent patients would lose the continuous glucose data streams they use to adjust therapy. Healthcare systems running remote patient monitoring programs would lose diabetes patient data feeds that are built into their electronic health records.
How does this company scale?
The smartphone app and cloud analytics that display and store glucose data can be extended to millions of additional users at almost no extra cost. What does not scale easily is the physical sensor: the glucose oxidase enzyme chemistry and the biocompatible adhesive formulation both require specialised biochemistry expertise that cannot be outsourced or automated, so manufacturing becomes a tighter bottleneck the faster the company tries to grow.
What external forces can significantly affect this company?
Medicare reimbursement rate changes for durable medical equipment directly affect how much the company earns per sensor and how many patients can afford one. If the FDA moves toward requiring more real-world evidence after a device is cleared, the cost of ongoing data collection rises. International supply chain disruptions for lithium battery components — the cells that power continuous 10-15 day operation — can delay sensor production.
Where is this company structurally vulnerable?
If the FDA issued new guidance treating the adhesive or the enzyme source as combination-product variables — meaning any change to either one requires a full new round of clinical trials — then any supply disruption that forced a reformulation would invalidate the existing clearance. That would cut off Medicare and insurance reimbursement and sever the certified data connections that insulin pumps like the Tandem t:slim depend on, all at once.
CompanyGraph